3 hours ago
1
- Olema Pharmaceuticals (NASDAQ:OLMA) plunged 30% in pre-market trading Monday after announcing new data from a phase 1b/2 trial of palazestrant in breast cancer.
- The candidate is under investigation in combination with Novartis' (NVS) Kisqali (ribociclib) for HR+/HER- advanced or metastatic breast cancer.
English (US) ·